CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands

Completed

Conditions: Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes
Leukemia, Myeloid, Acute

First Posted Date: 2016-09-07

Last Posted Date: 2019-07-24

Lead Sponsor: Celgene

Target Recruit Count: 209

Registration Number: NCT02891551

A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Phase 1

Terminated

Conditions: Neoplasms
Lymphoma, Non-Hodgkin

Interventions: Drug: CC-90011
Drug: Rifampicin
Drug: Itraconazole

First Posted Date: 2016-08-23

Last Posted Date: 2025-04-20

Lead Sponsor: Celgene

Target Recruit Count: 75

Registration Number: NCT02875223

Locations: 🇮🇹
Local Institution - 201, Milano, Italy
🇯🇵
Local Institution - 500, Kashiwa, Japan
🇯🇵
Local Institution - 501, Chuo-ku, Tokyo, Japan

and more 12 locations

A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)

Phase 1

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: CC-122
Drug: Nivolumab

First Posted Date: 2016-08-09

Last Posted Date: 2021-05-11

Lead Sponsor: Celgene

Target Recruit Count: 21

Registration Number: NCT02859324

Locations: 🇺🇸
UCLA Division of Hematology Oncology, Los Angeles, California, United States
🇪🇸
Hospital 12 de Octubre, Madrid, Spain
🇪🇸
Hospital Universitario Vall D Hebron, Barcelona, Spain

and more 11 locations

A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance

Completed

Conditions: Multiple Myeloma

Interventions: Other: Anti-myeloma treatment at physician discretion

First Posted Date: 2016-07-29

Last Posted Date: 2021-08-16

Lead Sponsor: Celgene

Target Recruit Count: 326

Registration Number: NCT02849444

Locations: 🇪🇸
Hospital Universitario Puerta del Mar, Cádiz, Andalucía, Spain
🇪🇸
Hospital Miguel Servet, Zaragoza, Aragón, Spain
🇪🇸
Hospital del Mar, Barcelona, Cataluña, Spain

and more 37 locations

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Phase 1

Terminated

Conditions: Leukemia, Myeloid, Acute
Myelodysplastic Syndromes

Interventions: Drug: CC-90009

First Posted Date: 2016-07-28

Last Posted Date: 2024-05-14

Lead Sponsor: Celgene

Target Recruit Count: 101

Registration Number: NCT02848001

Locations: 🇺🇸
Local Institution - 104, Hackensack, New Jersey, United States
🇨🇦
Local Institution - 201, Toronto, Ontario, Canada
🇳🇴
Local Institution - 701, Oslo, Norway

and more 17 locations

A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms

Completed

Conditions: Myelodysplastic Syndromes
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia Myeloid Acute
Multiple Myeloma

First Posted Date: 2016-07-22

Last Posted Date: 2017-07-26

Lead Sponsor: Celgene

Target Recruit Count: 117

Registration Number: NCT02842229

Locations: 🇪🇸
Hospital La Fe, Valencia, Spain
🇪🇸
Hospital de Segovia, Segovia, Spain
🇪🇸
Hospital Txagorritxu, Vitoria, Álava, Spain

and more 12 locations

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: CC-220
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2016-07-01

Last Posted Date: 2016-10-18

Lead Sponsor: Celgene Corporation

Target Recruit Count: 36

Registration Number: NCT02820935

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Durvalumab
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2016-06-21

Last Posted Date: 2023-02-21

Lead Sponsor: Celgene

Target Recruit Count: 37

Registration Number: NCT02807454

Locations: 🇺🇸
UCLA Division of Hematology Oncology, Los Angeles, California, United States
🇨🇦
Local Institution - 103, Saint John, New Brunswick, Canada
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 61 locations

Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: RPC1063

First Posted Date: 2016-06-13

Last Posted Date: 2018-03-27

Lead Sponsor: Celgene

Target Recruit Count: 22

Registration Number: NCT02797015

Locations: 🇺🇸
Breastlink Medical Group, Inc., Long Beach, California, United States
🇺🇸
Multiple Sclerosis Center at UCSF, San Francisco, California, United States
🇺🇸
Raleigh Neurology Associates PA, Raleigh, North Carolina, United States

and more 3 locations

Longterm Follow-up of Subjects Treated With bb2121

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Safety and efficacy assessments

First Posted Date: 2016-06-01

Last Posted Date: 2020-01-22

Lead Sponsor: Celgene

Target Recruit Count: 50

Registration Number: NCT02786511

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Stanford Cancer Center, Palo Alto, California, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy